PCR Technologies Market by Technique (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End User (Academia, Pharma-Biotech, Applied) - Global Forecast to 2027
The global PCR technologies Market market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0% from 2022 to 2027. Market growth is mainly driven by the rising incidence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and increasing investments. In addition, growing market penetration in emerging countries are expected to offer growth opportunities for players in the PCR technologies market.
POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.
Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
“The Reagents and Consumables segment accounted for the largest share of the PCR technologies market, by product, in 2021”
Based on products, the PCR technologies market is segmented into instruments, reagents and consumables, and software and services. In 2021, the largest share of the PCR technologies market was accounted by reagents and consumables segment, due to factors such as the increased dPCR application base and developing demand for dPCR based analytical procedures, among researchers and pharmaceutical-biotechtechnology companies. Moreover, bundle sales of PCR reagents with the purchase of PCR instruments and long term sales contract for PCR reagents upon device upgradation is also a major factor driving the adoption of PCR reagents and consumables in major markets.
“The real-time PCR (qPCR) segment accounted for the largest share of the PCR technologies market, by technique, in 2021”
Based on technique, the PCR technologies market is segmented into conventional PCR, real-time PCR (qPCR), digital PCR (dPCR), reverse transcription PCR (RT-PCR), hot-start PCR, multiplex PCR, and other PCR techniques. The real-time PCR (qPCR) segment accounted for the largest share of the market in 2021. Factors such as the ongoing automation of the laboratory techniques; expansion of qPCR applications, owing to real-time analysis and reduced analysis time; increased funding and investments for qPCR based research, rising number of probe-based multiplex genetic analysis procedures and large installation base of qPCR instruments are expected to fuel the growth of the real-time PCR market.
“The Diagnostic application segment, by application, accounted for the largest share of the global PCR technologies market in 2021”
On the basis of application, the PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid detection, nucleic acid synthesis, standard validation/verification, diagnostic applications, environmental applications, and other applications. The diagnostic application segment accounted for the largest share of the market in 2021. Major factor responsible is the significant evolution from a traditional DNA quantification technique into an advanced diagnostic technique having various diagnostic applications, such as prenatal screening test, rapid pathogen detection, disease diagnoses and the identification of blood-borne diseases during blood transfusion.
“On the basis of End Users, Hospitals and Diagnostic Centers segment accounted for the largest share of the global PCR technologies market, in 2021”
On the basis of end users, the PCR technologies market is segmented into hospitals and diagnostic centers, healthcare industry, academia and government organizations, pharma-biotech companies, applied industries, and other end users. The hospitals and diagnostic centers segment accounted for the largest share of the PCR technologies market in 2021. The rise in qPCR reagents market availability for clinical diagnostics, ongoing healthcare infrastructure expansion in emerging countries, and the continuous cost reduction of qPCR reagents are some of the factors that are driving the segment.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global PCR technologies market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. However, the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The high growth of this segment is mainly due to the ongoing of healthcare infrastructure expansion in emerging Asian countries, increasing number of genomics and cancer research projects in countries like China, India, and Japan, continuous government support for genomics-based researches in emerging Asia Pacific countries and rising outsourcing of clinical research by leading drug manufacturing companies to Asia-based CROs.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the PCR technologies market based on product, technique, application, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.
Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
- In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
- According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.
- According to the WHO, 1.2 million people in Southeast Asia suffer from malaria, with India alone accounting for ~76% of the total malaria cases.
- During 2014–2016, West Africa reported the largest Ebola epidemic in the region; in two and a half years, the outbreak resulted in more than 28,600 cases and 11,325 deaths.
- In 2020, an estimated 15,898 people in Brazil were at risk of Zika virus infections, down from over 30,000 cases reported a year earlier.
“The Reagents and Consumables segment accounted for the largest share of the PCR technologies market, by product, in 2021”
Based on products, the PCR technologies market is segmented into instruments, reagents and consumables, and software and services. In 2021, the largest share of the PCR technologies market was accounted by reagents and consumables segment, due to factors such as the increased dPCR application base and developing demand for dPCR based analytical procedures, among researchers and pharmaceutical-biotechtechnology companies. Moreover, bundle sales of PCR reagents with the purchase of PCR instruments and long term sales contract for PCR reagents upon device upgradation is also a major factor driving the adoption of PCR reagents and consumables in major markets.
“The real-time PCR (qPCR) segment accounted for the largest share of the PCR technologies market, by technique, in 2021”
Based on technique, the PCR technologies market is segmented into conventional PCR, real-time PCR (qPCR), digital PCR (dPCR), reverse transcription PCR (RT-PCR), hot-start PCR, multiplex PCR, and other PCR techniques. The real-time PCR (qPCR) segment accounted for the largest share of the market in 2021. Factors such as the ongoing automation of the laboratory techniques; expansion of qPCR applications, owing to real-time analysis and reduced analysis time; increased funding and investments for qPCR based research, rising number of probe-based multiplex genetic analysis procedures and large installation base of qPCR instruments are expected to fuel the growth of the real-time PCR market.
“The Diagnostic application segment, by application, accounted for the largest share of the global PCR technologies market in 2021”
On the basis of application, the PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid detection, nucleic acid synthesis, standard validation/verification, diagnostic applications, environmental applications, and other applications. The diagnostic application segment accounted for the largest share of the market in 2021. Major factor responsible is the significant evolution from a traditional DNA quantification technique into an advanced diagnostic technique having various diagnostic applications, such as prenatal screening test, rapid pathogen detection, disease diagnoses and the identification of blood-borne diseases during blood transfusion.
“On the basis of End Users, Hospitals and Diagnostic Centers segment accounted for the largest share of the global PCR technologies market, in 2021”
On the basis of end users, the PCR technologies market is segmented into hospitals and diagnostic centers, healthcare industry, academia and government organizations, pharma-biotech companies, applied industries, and other end users. The hospitals and diagnostic centers segment accounted for the largest share of the PCR technologies market in 2021. The rise in qPCR reagents market availability for clinical diagnostics, ongoing healthcare infrastructure expansion in emerging countries, and the continuous cost reduction of qPCR reagents are some of the factors that are driving the segment.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global PCR technologies market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. However, the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The high growth of this segment is mainly due to the ongoing of healthcare infrastructure expansion in emerging Asian countries, increasing number of genomics and cancer research projects in countries like China, India, and Japan, continuous government support for genomics-based researches in emerging Asia Pacific countries and rising outsourcing of clinical research by leading drug manufacturing companies to Asia-based CROs.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
- By Designation: C-level–10%, Director-level–14%, and Others–76%
- By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%
Research Coverage
This report studies the PCR technologies market based on product, technique, application, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the PCR technologies market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the PCR technologies market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the PCR technologies market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 KEY STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Indicative list of secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL PCR TECHNOLOGIES MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 6 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2021 VS. 2027 (USD MILLION)
FIGURE 7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION)
FIGURE 8 PCR TECHNOLOGIES MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PCR TECHNOLOGIES MARKET
4 PREMIUM INSIGHTS
4.1 PCR TECHNOLOGIES MARKET OVERVIEW
FIGURE 10 RISING INCIDENCE OF TARGET INFECTIOUS DISEASES AND GENETIC DISORDERS TO DRIVE MARKET GROWTH
4.2 PCR TECHNOLOGIES MARKET SHARE, BY TECHNIQUE, 2021 VS. 2027
FIGURE 11 REAL-TIME PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF PCR TECHNOLOGIES MARKET IN 2021
4.3 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION)
FIGURE 12 DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER AND COUNTRY (2021)
FIGURE 13 HOSPITALS AND DIAGNOSTIC CENTERS ARE LARGEST END-USERS OF PCR TECHNOLOGIES IN ASIA PACIFIC
4.5 PCR TECHNOLOGIES MARKET, BY REGION
FIGURE 14 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD (2022–2027)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of target infectious diseases and genetic disorders
FIGURE 16 GLOBAL BURDEN OF HIV INFECTIONS, BY REGION, 2021
FIGURE 17 GROWING GERIATRIC POPULATION ACROSS KEY GEOGRAPHIES, 2019 VS. 2050 (MILLION)
5.2.1.2 Continuous advancements in PCR technologies
TABLE 1 TRADITIONAL PCR VS. QPCR AND DPCR
5.2.1.3 Increasing investments, funds, and grants
5.2.1.4 Increasing use of biomarker profiling for disease diagnostics
5.2.1.5 Successful completion of Human Genome Project
5.2.2 RESTRAINTS
5.2.2.1 High device costs associated with dPCR
5.2.2.2 Technical limitations of qPCR and dPCR
5.2.3 OPPORTUNITIES
5.2.3.1 Growing market penetration in emerging countries
5.2.3.2 Shift from plant-derived to genome-based drug discovery
5.2.4 CHALLENGES
5.2.4.1 Adoption and implementation of MIQE guidelines
5.3 TECHNOLOGY ANALYSIS
5.3.1 DEVELOPMENT OF PORTABLE INSTRUMENTS USING PCR DIAGNOSTIC SERVICES
5.3.2 DEVELOPMENT OF RAPID AND SENSITIVE DIAGNOSTIC KITS
5.4 GLOBAL REGULATORY LANDSCAPE
5.4.1 KEY REGULATORY AGENCIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 19 SUPPLY CHAIN ANALYSIS
5.7 PRICING TREND ANALYSIS
TABLE 2 AVERAGE PRICE OF PCR PRODUCTS, BY KEY PLAYER, 2021 (USD)
FIGURE 20 AVERAGE PRICE OF DIFFERENT PCR ANALYZERS, BY TECHNOLOGY, 2021 (USD)
5.8 REIMBURSEMENT SCENARIO
TABLE 3 REIMBURSEMENT CODES FOR COVID-19 PCR TESTING IN US (AS OF 2022)
5.9 ECOSYSTEM COVERAGE: PARENT MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 OVERVIEW
TABLE 4 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.2 DEGREE OF COMPETITION
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 THREAT OF NEW ENTRANTS
5.10.6 THREAT OF SUBSTITUTES
5.11 PATENT ANALYSIS
FIGURE 21 NUMBER OF PATENTS FOR PCR TESTING
FIGURE 22 NUMBER OF PATENTS FOR PCR DIAGNOSTICS
5.12 TRADE ANALYSIS
TABLE 5 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
TABLE 6 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.13 KEY CONFERENCES AND EVENTS (2022–2023)
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR CONFERENCES AND EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 DEVELOPMENT OF COMPACT, PORTABLE, AND LAB-ON-CHIP PCR DEVICES
5.14.2 ONGOING TECHNOLOGICAL INTEGRATION WITH PCR PROCESS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS, BY END USER
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER
TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER (%)
5.15.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA, BY END USER
TABLE 9 KEY BUYING CRITERIA, BY END USER
6 PCR TECHNOLOGIES MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 10 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 REAGENTS AND CONSUMABLES
6.2.1 INCREASING NUMBER OF ANALYTICAL PROCEDURES AMONG RESEARCHERS TO FUEL MARKET GROWTH
TABLE 11 PCR REAGENTS AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING AVAILABILITY OF INNOVATIVE PCR INSTRUMENTS TO DRIVE MARKET GROWTH
TABLE 12 PCR INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SOFTWARE AND SERVICES
6.4.1 AUTOMATION AND DIGITALIZATION OF LABORATORY PROCESSES TO FUEL ADOPTION AMONG END USERS
TABLE 13 PCR SOFTWARE AND SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE
7.1 INTRODUCTION
TABLE 14 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
7.2 CONVENTIONAL PCR
7.2.1 DIVERSE APPLICATIONS OF CONVENTIONAL PCR TO SUSTAIN MARKET GROWTH
TABLE 15 CONVENTIONAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 CONVENTIONAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 17 CONVENTIONAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 18 CONVENTIONAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.3 REAL-TIME PCR
7.3.1 GROWING ADOPTION AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO FUEL MARKET GROWTH
TABLE 19 REAL-TIME PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 REAL-TIME PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 21 REAL-TIME PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 22 REAL-TIME PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.4 DIGITAL PCR
7.4.1 ONGOING TECHNOLOGICAL DEVELOPMENTS WITH RESPECT TO DIGITAL PCR TO DRIVE MARKET GROWTH
TABLE 23 DIGITAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 DIGITAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 25 DIGITAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 26 DIGITAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.5 REVERSE TRANSCRIPTION PCR
7.5.1 HIGHER SENSITIVITY FOR MRNA DETECTION TO DRIVE MARKET GROWTH
TABLE 27 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
TABLE 28 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 30 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 31 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.6 HOT-START PCR
7.6.1 HASSLE-FREE SETUP OF SAMPLES KEY ADVANTAGE OFFERED BY HOT-START PCR
TABLE 32 BENEFITS AND CONSIDERATIONS INVOLVED IN HOT-START TECHNOLOGY
TABLE 33 HOT-START PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 HOT-START PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 35 HOT-START PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 36 HOT-START PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.7 MULTIPLEX PCR
7.7.1 COST-EFFECTIVENESS OF THIS TECHNIQUE TO DRIVE MARKET GROWTH
TABLE 37 MULTIPLEX PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 MULTIPLEX PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 39 MULTIPLEX PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 40 MULTIPLEX PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.8 OTHER PCR TECHNIQUES
TABLE 41 OTHER PCR TECHNIQUES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 43 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 44 OTHER PCR TECHNIQUES MARKET, BY END USER, 2020–2027 (USD MILLION)
8 PCR TECHNOLOGIES MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 45 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 GENE EXPRESSION ANALYSIS
8.2.1 GENE EXPRESSION ANALYSIS WIDELY USED IN EPIGENETICS, SIRNA QUANTIFICATION, MRNA ANALYSIS, AND CELL LINE VALIDATION
TABLE 46 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2020–2027 (USD MILLION)
8.3 GENETIC SEQUENCING
8.3.1 REDUCED COST OF SEQUENCING TO DRIVE MARKET GROWTH
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.4 GENOTYPING
8.4.1 SNP GENOTYPING CAN ACCELERATE PERSONALIZED MEDICINE DEVELOPMENT
TABLE 48 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2020–2027 (USD MILLION)
8.5 NUCLEIC ACID DETECTION
8.5.1 PCR TECHNIQUES HAVE WIDE APPLICATIONS IN NUCLEIC ACID DETECTION
TABLE 49 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2020–2027 (USD MILLION)
8.6 NUCLEIC ACID SYNTHESIS
8.6.1 DNA SYNTHESIS HAS OPENED AVENUES FOR PROGRESS IN BIOLOGY
TABLE 50 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2020–2027 (USD MILLION)
8.7 STANDARD VALIDATION/VERIFICATION
8.7.1 PCR TECHNIQUES USED FOR REGIONAL/GLOBAL VALIDATION TO FRAME COMMERCIAL/NON-COMMERCIAL GUIDELINES
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2020–2027 (USD MILLION)
8.8 DIAGNOSTIC APPLICATIONS
8.8.1 DIAGNOSTIC APPLICATIONS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
TABLE 52 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.9 ENVIRONMENTAL APPLICATIONS
8.9.1 PCR WIDELY USED TO DETECT PATHOGENS IN ENVIRONMENTAL SAMPLES
TABLE 53 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.10 OTHER APPLICATIONS
TABLE 54 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9 PCR TECHNOLOGIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 55 PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS AND DIAGNOSTIC CENTERS
9.2.1 HIGH PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH
TABLE 56 PCR TECHNOLOGIES MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION)
9.3 HEALTHCARE INDUSTRY
9.3.1 PCR HAS WIDE APPLICATIONS IN HEALTHCARE INDUSTRY
TABLE 57 PCR TECHNOLOGIES MARKET FOR HEALTHCARE INDUSTRY, BY REGION, 2020–2027 (USD MILLION)
9.4 ACADEMIA AND GOVERNMENT ORGANIZATIONS
9.4.1 AVAILABILITY OF COST-EFFECTIVE AND INNOVATIVE PCR PRODUCTS TO DRIVE ADOPTION
TABLE 58 PCR TECHNOLOGIES MARKET FOR ACADEMIA AND GOVERNMENT ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5 PHARMA-BIOTECH COMPANIES
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO FUEL ADOPTION OF PCR TECHNOLOGIES
TABLE 59 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2020–2027 (USD MILLION)
9.6 APPLIED INDUSTRIES
9.6.1 INCREASING ENVIRONMENTAL REGULATIONS TO DRIVE ADOPTION OF PCR TECHNIQUES
TABLE 60 PCR TECHNOLOGIES MARKET FOR APPLIED INDUSTRIES, BY REGION, 2020–2027 (USD MILLION)
9.7 OTHER END USERS
TABLE 61 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 PCR TECHNOLOGIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 62 PCR TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Growing adoption of PCR techniques in research and academia to drive market growth
TABLE 68 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Government initiatives for supporting genomics research to propel growth
TABLE 69 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Large-scale outsourcing of clinical diagnostic testing by hospitals to drive market growth
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing focus on genomics research to support market growth
TABLE 76 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Initiatives for developing genomic medicine to support market growth
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing R&D investments by pharmaceutical companies to propel market growth
TABLE 78 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing prevalence of chronic and infectious diseases to drive market growth
TABLE 79 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 80 REST OF EUROPE: HIV AND TB INCIDENCE, BY COUNTRY, 2020
TABLE 81 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
TABLE 82 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 84 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 85 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Strong research and healthcare infrastructure to support market growth
TABLE 87 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure modernization to support market growth
TABLE 88 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Presence of large target patient population to support market growth
TABLE 89 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 High healthcare expenditure to drive demand for advanced healthcare technologies such as PCR
TABLE 90 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Growing number of private hospitals and independent testing laboratories to drive market growth
TABLE 91 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 92 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
TABLE 93 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 95 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 96 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 97 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil to dominate LATAM market during forecast period
TABLE 98 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
TABLE 99 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 100 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LOW PURCHASING POWER OF END USERS AND INFRASTRUCTURAL LIMITATIONS TO RESTRAIN MARKET GROWTH
TABLE 101 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN PCR TECHNOLOGIES MARKET, 2018–2022
11.2 REVENUE SHARE ANALYSIS
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PCR TECHNOLOGIES MARKET
11.3 MARKET SHARE ANALYSIS
FIGURE 29 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2021
11.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021)
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 30 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
11.5 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME EVALUATION QUADRANT (2021)
11.5.1 PROGRESSIVE COMPANIES
11.5.2 RESPONSIVE COMPANIES
11.5.3 DYNAMIC COMPANIES
11.5.4 STARTING BLOCKS
FIGURE 31 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS (2021)
11.6 COMPETITIVE SCENARIO
11.6.1 PRODUCT LAUNCHES & APPROVALS
11.6.2 DEALS
11.6.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 105 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 106 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
12.1.3 BIO-RAD LABORATORIES, INC.
TABLE 107 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.4 QIAGEN N.V.
TABLE 108 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.5 TAKARA BIO, INC.
TABLE 109 TAKARA BIO, INC.: BUSINESS OVERVIEW
FIGURE 36 TAKARA BIO, INC.: COMPANY SNAPSHOT (2021)
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 110 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.7 BIOM?RIEUX S.A.
TABLE 111 BIOM?RIEUX S.A.: BUSINESS OVERVIEW
FIGURE 38 BIOM?RIEUX S.A.: COMPANY SNAPSHOT (2021)
12.1.8 FLUIDIGM CORPORATION
TABLE 112 FLUIDIGM CORPORATION: BUSINESS OVERVIEW
FIGURE 39 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2021)
12.1.9 DANAHER CORPORATION
TABLE 113 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.10 ABBOTT LABORATORIES
TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.11 MERCK KGAA
TABLE 115 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.12 BECTON, DICKINSON AND COMPANY
TABLE 116 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
12.1.13 PROMEGA CORPORATION
TABLE 117 PROMEGA CORPORATION: BUSINESS OVERVIEW
12.1.14 EPPENDORF AG
TABLE 118 EPPENDORF AG: BUSINESS OVERVIEW
FIGURE 44 EPPENDORF AG: COMPANY SNAPSHOT (2021)
12.1.15 ANALYTIK JENA AG (A WHOLLY OWNED SUBSIDIARY OF ENDRESS+HAUSER AG)
TABLE 119 ENDRESS+HAUSER: BUSINESS OVERVIEW
FIGURE 45 ENDRESS+HAUSER: COMPANY SNAPSHOT (2021)
12.2 OTHER PLAYERS
12.2.1 MERIDIAN BIOSCIENCE, INC.
12.2.2 STILLA TECHNOLOGIES
12.2.3 JN MEDSYS
12.2.4 AVANCE BIOSCIENCES INC.
12.2.5 LGC BIOSEARCH TECHNOLOGIES
12.2.6 AZURA GENOMICS INC.
12.2.7 BIONEER CORPORATION
12.2.8 BLUE-RAY BIOTECH
12.2.9 LUMINEX CORPORATION (A DIASORIN COMPANY)
12.2.10 BIO MOLECULAR SYSTEMS
12.2.11 AZURE BIOSYSTEMS
12.2.12 CHAI INC.
12.2.13 ENZO LIFE SCIENCES
12.2.14 BIOMEME, INC.
12.2.15 ELITECH GROUP SAS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 KEY STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Indicative list of secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL PCR TECHNOLOGIES MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 6 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2021 VS. 2027 (USD MILLION)
FIGURE 7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION)
FIGURE 8 PCR TECHNOLOGIES MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PCR TECHNOLOGIES MARKET
4 PREMIUM INSIGHTS
4.1 PCR TECHNOLOGIES MARKET OVERVIEW
FIGURE 10 RISING INCIDENCE OF TARGET INFECTIOUS DISEASES AND GENETIC DISORDERS TO DRIVE MARKET GROWTH
4.2 PCR TECHNOLOGIES MARKET SHARE, BY TECHNIQUE, 2021 VS. 2027
FIGURE 11 REAL-TIME PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF PCR TECHNOLOGIES MARKET IN 2021
4.3 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION)
FIGURE 12 DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER AND COUNTRY (2021)
FIGURE 13 HOSPITALS AND DIAGNOSTIC CENTERS ARE LARGEST END-USERS OF PCR TECHNOLOGIES IN ASIA PACIFIC
4.5 PCR TECHNOLOGIES MARKET, BY REGION
FIGURE 14 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD (2022–2027)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of target infectious diseases and genetic disorders
FIGURE 16 GLOBAL BURDEN OF HIV INFECTIONS, BY REGION, 2021
FIGURE 17 GROWING GERIATRIC POPULATION ACROSS KEY GEOGRAPHIES, 2019 VS. 2050 (MILLION)
5.2.1.2 Continuous advancements in PCR technologies
TABLE 1 TRADITIONAL PCR VS. QPCR AND DPCR
5.2.1.3 Increasing investments, funds, and grants
5.2.1.4 Increasing use of biomarker profiling for disease diagnostics
5.2.1.5 Successful completion of Human Genome Project
5.2.2 RESTRAINTS
5.2.2.1 High device costs associated with dPCR
5.2.2.2 Technical limitations of qPCR and dPCR
5.2.3 OPPORTUNITIES
5.2.3.1 Growing market penetration in emerging countries
5.2.3.2 Shift from plant-derived to genome-based drug discovery
5.2.4 CHALLENGES
5.2.4.1 Adoption and implementation of MIQE guidelines
5.3 TECHNOLOGY ANALYSIS
5.3.1 DEVELOPMENT OF PORTABLE INSTRUMENTS USING PCR DIAGNOSTIC SERVICES
5.3.2 DEVELOPMENT OF RAPID AND SENSITIVE DIAGNOSTIC KITS
5.4 GLOBAL REGULATORY LANDSCAPE
5.4.1 KEY REGULATORY AGENCIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 19 SUPPLY CHAIN ANALYSIS
5.7 PRICING TREND ANALYSIS
TABLE 2 AVERAGE PRICE OF PCR PRODUCTS, BY KEY PLAYER, 2021 (USD)
FIGURE 20 AVERAGE PRICE OF DIFFERENT PCR ANALYZERS, BY TECHNOLOGY, 2021 (USD)
5.8 REIMBURSEMENT SCENARIO
TABLE 3 REIMBURSEMENT CODES FOR COVID-19 PCR TESTING IN US (AS OF 2022)
5.9 ECOSYSTEM COVERAGE: PARENT MARKET
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 OVERVIEW
TABLE 4 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.2 DEGREE OF COMPETITION
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 THREAT OF NEW ENTRANTS
5.10.6 THREAT OF SUBSTITUTES
5.11 PATENT ANALYSIS
FIGURE 21 NUMBER OF PATENTS FOR PCR TESTING
FIGURE 22 NUMBER OF PATENTS FOR PCR DIAGNOSTICS
5.12 TRADE ANALYSIS
TABLE 5 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
TABLE 6 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.13 KEY CONFERENCES AND EVENTS (2022–2023)
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR CONFERENCES AND EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 DEVELOPMENT OF COMPACT, PORTABLE, AND LAB-ON-CHIP PCR DEVICES
5.14.2 ONGOING TECHNOLOGICAL INTEGRATION WITH PCR PROCESS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS, BY END USER
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER
TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER (%)
5.15.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA, BY END USER
TABLE 9 KEY BUYING CRITERIA, BY END USER
6 PCR TECHNOLOGIES MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 10 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 REAGENTS AND CONSUMABLES
6.2.1 INCREASING NUMBER OF ANALYTICAL PROCEDURES AMONG RESEARCHERS TO FUEL MARKET GROWTH
TABLE 11 PCR REAGENTS AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING AVAILABILITY OF INNOVATIVE PCR INSTRUMENTS TO DRIVE MARKET GROWTH
TABLE 12 PCR INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SOFTWARE AND SERVICES
6.4.1 AUTOMATION AND DIGITALIZATION OF LABORATORY PROCESSES TO FUEL ADOPTION AMONG END USERS
TABLE 13 PCR SOFTWARE AND SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE
7.1 INTRODUCTION
TABLE 14 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
7.2 CONVENTIONAL PCR
7.2.1 DIVERSE APPLICATIONS OF CONVENTIONAL PCR TO SUSTAIN MARKET GROWTH
TABLE 15 CONVENTIONAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 CONVENTIONAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 17 CONVENTIONAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 18 CONVENTIONAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.3 REAL-TIME PCR
7.3.1 GROWING ADOPTION AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO FUEL MARKET GROWTH
TABLE 19 REAL-TIME PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 REAL-TIME PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 21 REAL-TIME PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 22 REAL-TIME PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.4 DIGITAL PCR
7.4.1 ONGOING TECHNOLOGICAL DEVELOPMENTS WITH RESPECT TO DIGITAL PCR TO DRIVE MARKET GROWTH
TABLE 23 DIGITAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 DIGITAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 25 DIGITAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 26 DIGITAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.5 REVERSE TRANSCRIPTION PCR
7.5.1 HIGHER SENSITIVITY FOR MRNA DETECTION TO DRIVE MARKET GROWTH
TABLE 27 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
TABLE 28 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 30 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 31 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.6 HOT-START PCR
7.6.1 HASSLE-FREE SETUP OF SAMPLES KEY ADVANTAGE OFFERED BY HOT-START PCR
TABLE 32 BENEFITS AND CONSIDERATIONS INVOLVED IN HOT-START TECHNOLOGY
TABLE 33 HOT-START PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 HOT-START PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 35 HOT-START PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 36 HOT-START PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.7 MULTIPLEX PCR
7.7.1 COST-EFFECTIVENESS OF THIS TECHNIQUE TO DRIVE MARKET GROWTH
TABLE 37 MULTIPLEX PCR MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 MULTIPLEX PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 39 MULTIPLEX PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 40 MULTIPLEX PCR MARKET, BY END USER, 2020–2027 (USD MILLION)
7.8 OTHER PCR TECHNIQUES
TABLE 41 OTHER PCR TECHNIQUES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 43 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 44 OTHER PCR TECHNIQUES MARKET, BY END USER, 2020–2027 (USD MILLION)
8 PCR TECHNOLOGIES MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 45 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 GENE EXPRESSION ANALYSIS
8.2.1 GENE EXPRESSION ANALYSIS WIDELY USED IN EPIGENETICS, SIRNA QUANTIFICATION, MRNA ANALYSIS, AND CELL LINE VALIDATION
TABLE 46 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2020–2027 (USD MILLION)
8.3 GENETIC SEQUENCING
8.3.1 REDUCED COST OF SEQUENCING TO DRIVE MARKET GROWTH
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.4 GENOTYPING
8.4.1 SNP GENOTYPING CAN ACCELERATE PERSONALIZED MEDICINE DEVELOPMENT
TABLE 48 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2020–2027 (USD MILLION)
8.5 NUCLEIC ACID DETECTION
8.5.1 PCR TECHNIQUES HAVE WIDE APPLICATIONS IN NUCLEIC ACID DETECTION
TABLE 49 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2020–2027 (USD MILLION)
8.6 NUCLEIC ACID SYNTHESIS
8.6.1 DNA SYNTHESIS HAS OPENED AVENUES FOR PROGRESS IN BIOLOGY
TABLE 50 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2020–2027 (USD MILLION)
8.7 STANDARD VALIDATION/VERIFICATION
8.7.1 PCR TECHNIQUES USED FOR REGIONAL/GLOBAL VALIDATION TO FRAME COMMERCIAL/NON-COMMERCIAL GUIDELINES
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2020–2027 (USD MILLION)
8.8 DIAGNOSTIC APPLICATIONS
8.8.1 DIAGNOSTIC APPLICATIONS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE
TABLE 52 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.9 ENVIRONMENTAL APPLICATIONS
8.9.1 PCR WIDELY USED TO DETECT PATHOGENS IN ENVIRONMENTAL SAMPLES
TABLE 53 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.10 OTHER APPLICATIONS
TABLE 54 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9 PCR TECHNOLOGIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 55 PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS AND DIAGNOSTIC CENTERS
9.2.1 HIGH PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH
TABLE 56 PCR TECHNOLOGIES MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION)
9.3 HEALTHCARE INDUSTRY
9.3.1 PCR HAS WIDE APPLICATIONS IN HEALTHCARE INDUSTRY
TABLE 57 PCR TECHNOLOGIES MARKET FOR HEALTHCARE INDUSTRY, BY REGION, 2020–2027 (USD MILLION)
9.4 ACADEMIA AND GOVERNMENT ORGANIZATIONS
9.4.1 AVAILABILITY OF COST-EFFECTIVE AND INNOVATIVE PCR PRODUCTS TO DRIVE ADOPTION
TABLE 58 PCR TECHNOLOGIES MARKET FOR ACADEMIA AND GOVERNMENT ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5 PHARMA-BIOTECH COMPANIES
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO FUEL ADOPTION OF PCR TECHNOLOGIES
TABLE 59 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2020–2027 (USD MILLION)
9.6 APPLIED INDUSTRIES
9.6.1 INCREASING ENVIRONMENTAL REGULATIONS TO DRIVE ADOPTION OF PCR TECHNIQUES
TABLE 60 PCR TECHNOLOGIES MARKET FOR APPLIED INDUSTRIES, BY REGION, 2020–2027 (USD MILLION)
9.7 OTHER END USERS
TABLE 61 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 PCR TECHNOLOGIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 62 PCR TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Growing adoption of PCR techniques in research and academia to drive market growth
TABLE 68 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Government initiatives for supporting genomics research to propel growth
TABLE 69 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Large-scale outsourcing of clinical diagnostic testing by hospitals to drive market growth
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Growing focus on genomics research to support market growth
TABLE 76 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Initiatives for developing genomic medicine to support market growth
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing R&D investments by pharmaceutical companies to propel market growth
TABLE 78 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing prevalence of chronic and infectious diseases to drive market growth
TABLE 79 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 80 REST OF EUROPE: HIV AND TB INCIDENCE, BY COUNTRY, 2020
TABLE 81 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
TABLE 82 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 84 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 85 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Strong research and healthcare infrastructure to support market growth
TABLE 87 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure modernization to support market growth
TABLE 88 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Presence of large target patient population to support market growth
TABLE 89 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 High healthcare expenditure to drive demand for advanced healthcare technologies such as PCR
TABLE 90 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Growing number of private hospitals and independent testing laboratories to drive market growth
TABLE 91 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 92 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
TABLE 93 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 95 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 96 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 97 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil to dominate LATAM market during forecast period
TABLE 98 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
TABLE 99 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 100 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 LOW PURCHASING POWER OF END USERS AND INFRASTRUCTURAL LIMITATIONS TO RESTRAIN MARKET GROWTH
TABLE 101 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN PCR TECHNOLOGIES MARKET, 2018–2022
11.2 REVENUE SHARE ANALYSIS
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PCR TECHNOLOGIES MARKET
11.3 MARKET SHARE ANALYSIS
FIGURE 29 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2021
11.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021)
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 30 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
11.5 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME EVALUATION QUADRANT (2021)
11.5.1 PROGRESSIVE COMPANIES
11.5.2 RESPONSIVE COMPANIES
11.5.3 DYNAMIC COMPANIES
11.5.4 STARTING BLOCKS
FIGURE 31 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS (2021)
11.6 COMPETITIVE SCENARIO
11.6.1 PRODUCT LAUNCHES & APPROVALS
11.6.2 DEALS
11.6.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 105 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 106 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
12.1.3 BIO-RAD LABORATORIES, INC.
TABLE 107 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.4 QIAGEN N.V.
TABLE 108 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.5 TAKARA BIO, INC.
TABLE 109 TAKARA BIO, INC.: BUSINESS OVERVIEW
FIGURE 36 TAKARA BIO, INC.: COMPANY SNAPSHOT (2021)
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 110 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.7 BIOM?RIEUX S.A.
TABLE 111 BIOM?RIEUX S.A.: BUSINESS OVERVIEW
FIGURE 38 BIOM?RIEUX S.A.: COMPANY SNAPSHOT (2021)
12.1.8 FLUIDIGM CORPORATION
TABLE 112 FLUIDIGM CORPORATION: BUSINESS OVERVIEW
FIGURE 39 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2021)
12.1.9 DANAHER CORPORATION
TABLE 113 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.10 ABBOTT LABORATORIES
TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.11 MERCK KGAA
TABLE 115 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.12 BECTON, DICKINSON AND COMPANY
TABLE 116 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
12.1.13 PROMEGA CORPORATION
TABLE 117 PROMEGA CORPORATION: BUSINESS OVERVIEW
12.1.14 EPPENDORF AG
TABLE 118 EPPENDORF AG: BUSINESS OVERVIEW
FIGURE 44 EPPENDORF AG: COMPANY SNAPSHOT (2021)
12.1.15 ANALYTIK JENA AG (A WHOLLY OWNED SUBSIDIARY OF ENDRESS+HAUSER AG)
TABLE 119 ENDRESS+HAUSER: BUSINESS OVERVIEW
FIGURE 45 ENDRESS+HAUSER: COMPANY SNAPSHOT (2021)
12.2 OTHER PLAYERS
12.2.1 MERIDIAN BIOSCIENCE, INC.
12.2.2 STILLA TECHNOLOGIES
12.2.3 JN MEDSYS
12.2.4 AVANCE BIOSCIENCES INC.
12.2.5 LGC BIOSEARCH TECHNOLOGIES
12.2.6 AZURA GENOMICS INC.
12.2.7 BIONEER CORPORATION
12.2.8 BLUE-RAY BIOTECH
12.2.9 LUMINEX CORPORATION (A DIASORIN COMPANY)
12.2.10 BIO MOLECULAR SYSTEMS
12.2.11 AZURE BIOSYSTEMS
12.2.12 CHAI INC.
12.2.13 ENZO LIFE SCIENCES
12.2.14 BIOMEME, INC.
12.2.15 ELITECH GROUP SAS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
